@article{fusarpoli2013,
  title = {The psychosis high-risk state: a comprehensive state-of-the-art review},
  author = {Fusar-Poli P and Borgwardt S and others},
  journal = {JAMA Psychiatry},
  year = {2013},
  volume = {70},
  number = {1},
  pages = {107--120},
  doi = {10.1001/jamapsychiatry.2013.269},
  note = {PMID: 23165428}
}

@article{addington2011,
  title = {At clinical high risk for psychosis: outcome for nonconverters},
  author = {Addington J and Cornblatt BA and Cadenhead KS and others},
  journal = {Am J Psychiatry},
  year = {2011},
  volume = {168},
  number = {8},
  pages = {800--805},
  doi = {10.1176/appi.ajp.2011.10081191},
  note = {PMID: 21498462}
}

@article{fusarpoli2012,
  title = {Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk},
  author = {Fusar-Poli P and Bonoldi I and Yung AR and others},
  journal = {Arch Gen Psychiatry},
  year = {2012},
  volume = {69},
  number = {3},
  pages = {220--229},
  doi = {10.1001/archgenpsychiatry.2011.1472},
  note = {PMID: 22393215}
}

@article{salazar2021,
  title = {Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis},
  author = {Salazar de Pablo G and Radua J and Pereira J and others},
  journal = {JAMA Psychiatry},
  year = {2021},
  volume = {78},
  number = {9},
  pages = {970--978},
  doi = {10.1001/jamapsychiatry.2021.0830},
  note = {PMID: 34259821}
}

@misc{nicecg178,
  title = {Psychosis and schizophrenia in adults: prevention and management (CG178)},
  author = {{National Institute for Health and Care Excellence}},
  journal = {NICE clinical guideline},
  year = {2014},
  note = {Published 12 February 2014; last updated 4 September 2026},
  url = {https://www.nice.org.uk/guidance/cg178}
}

@misc{nicecg155,
  title = {Psychosis and schizophrenia in children and young people: recognition and management (CG155)},
  author = {{National Institute for Health and Care Excellence}},
  journal = {NICE clinical guideline},
  year = {2013},
  note = {Published 23 January 2013; last updated 26 October 2016},
  url = {https://www.nice.org.uk/guidance/cg155}
}

@misc{epidyolexsmpc,
  title = {Epidyolex 100 mg/ml oral solution: Summary of Product Characteristics},
  journal = {Electronic Medicines Compendium},
  note = {Date of revision of the text 8 June 2026},
  url = {https://www.medicines.org.uk/emc/product/10781}
}

@article{devinsky2017,
  title = {Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome},
  author = {Devinsky O and others},
  journal = {N Engl J Med},
  year = {2017},
  volume = {376},
  number = {21},
  pages = {2011--2020},
  doi = {10.1056/NEJMoa1611618},
  note = {PMID: 28538134}
}

@article{diforti2019,
  title = {The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study},
  author = {Di Forti M and others},
  journal = {Lancet Psychiatry},
  year = {2019},
  volume = {6},
  number = {5},
  pages = {427--436},
  doi = {10.1016/S2215-0366(19)30048-3},
  note = {PMID: 30902669}
}

@article{bhattacharyya2010,
  title = {Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology},
  author = {Bhattacharyya S and Morrison PD and Fusar-Poli P and others},
  journal = {Neuropsychopharmacology},
  year = {2010},
  volume = {35},
  number = {3},
  pages = {764--774},
  doi = {10.1038/npp.2009.184},
  note = {PMID: 19924114}
}

@article{mcguire2018,
  title = {Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial},
  author = {McGuire P and Robson P and Cubala WJ and others},
  journal = {Am J Psychiatry},
  year = {2018},
  volume = {175},
  number = {3},
  pages = {225--231},
  doi = {10.1176/appi.ajp.2017.17030325},
  note = {PMID: 29241357}
}

@article{leweke2012,
  title = {Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia},
  author = {Leweke FM and others},
  journal = {Transl Psychiatry},
  year = {2012},
  volume = {2},
  number = {3},
  pages = {e94},
  doi = {10.1038/tp.2012.15},
  note = {PMID: 22832859}
}

@article{boggs2018,
  title = {The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomized placebo controlled trial},
  author = {Boggs DL and Surti T and others},
  journal = {Psychopharmacology (Berl)},
  year = {2018},
  volume = {235},
  number = {7},
  pages = {1923--1932},
  doi = {10.1007/s00213-018-4885-9},
  note = {PMID: 29619533}
}

@article{bhattacharyya2018,
  title = {Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial},
  author = {Bhattacharyya S and others},
  journal = {JAMA Psychiatry},
  year = {2018},
  volume = {75},
  number = {11},
  pages = {1107--1117},
  doi = {10.1001/jamapsychiatry.2018.2309},
  note = {PMID: 30167644}
}

@article{appiahkusi2020,
  title = {Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis},
  author = {Appiah-Kusi E and others},
  journal = {Psychopharmacology (Berl)},
  year = {2020},
  volume = {237},
  number = {4},
  pages = {1121--1130},
  doi = {10.1007/s00213-019-05442-6},
  note = {PMID: 31915861}
}

@article{bhattacharyya2024,
  title = {Effects of cannabidiol on symptoms in people at clinical high risk for psychosis},
  author = {Bhattacharyya S and Appiah-Kusi E and Wilson R and others},
  journal = {World Psychiatry},
  year = {2024},
  volume = {23},
  number = {3},
  pages = {451--452},
  doi = {10.1002/wps.21253},
  note = {PMID: 39279373}
}

@article{cantop,
  title = {Cannabidiol as a treatment for patients who are clinically at high risk of developing psychosis: learnings from the CANTOP-RCT},
  author = {Bhattacharyya S and Davies C and Carter B and McGuire P and Brammer M and Fusar-Poli P and Broome M and Watson S and Perez J and Yung A},
  journal = {Efficacy and Mechanism Evaluation},
  publisher = {NIHR Journals Library},
  year = {2026},
  volume = {13},
  number = {7},
  pages = {197--214},
  doi = {10.3310/YNFH9826},
  note = {Published March 2025. PMID: 40096425}
}

@misc{nct07186283,
  title = {A Phase 1 study to assess the safety and pharmacokinetics of novel cannabidiol (CBD) soft-gel capsule formulation (NW300EMCBD) in healthy subjects},
  author = {{NW PharmaTech Ltd (sponsor)}},
  journal = {ClinicalTrials.gov NCT07186283; ISRCTN25163383},
  year = {2025},
  doi = {10.1186/ISRCTN25163383},
  url = {https://clinicaltrials.gov/study/NCT07186283}
}

@article{salazarprev2021,
  title = {Prevalence of individuals at clinical high-risk of psychosis in the general population and clinical samples: systematic review and meta-analysis},
  author = {Salazar de Pablo G and Woods SW and Drymonitou G and de Diego H and Fusar-Poli P},
  journal = {Brain Sci},
  year = {2021},
  volume = {11},
  number = {11},
  pages = {1544},
  doi = {10.3390/brainsci11111544},
  note = {PMID: 34827543}
}

@article{stafford2013,
  title = {Early interventions to prevent psychosis: systematic review and meta-analysis},
  author = {Stafford MR and others},
  journal = {BMJ},
  year = {2013},
  volume = {346},
  pages = {f185},
  doi = {10.1136/bmj.f185},
  note = {PMID: 23335473}
}

@article{davies2018,
  title = {Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis},
  author = {Davies C and others},
  journal = {World Psychiatry},
  year = {2018},
  volume = {17},
  number = {2},
  pages = {196--209},
  doi = {10.1002/wps.20526},
  note = {PMID: 29856551}
}

@article{kane2016,
  title = {Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program},
  author = {Kane JM and others},
  journal = {Am J Psychiatry},
  year = {2016},
  volume = {173},
  number = {4},
  pages = {362--372},
  doi = {10.1176/appi.ajp.2015.15050632},
  note = {PMID: 26481174}
}

@article{perucca2020,
  title = {Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications},
  author = {Perucca E and Bialer M},
  journal = {CNS Drugs},
  year = {2020},
  volume = {34},
  number = {8},
  pages = {795--800},
  doi = {10.1007/s40263-020-00741-5},
  note = {PMID: 32504461}
}

@article{taylor2018,
  title = {A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects},
  author = {Taylor L and others},
  journal = {CNS Drugs},
  year = {2018},
  volume = {32},
  number = {11},
  pages = {1053--1067},
  doi = {10.1007/s40263-018-0578-5},
  note = {PMID: 30374683}
}

% NWPT-048 start (Science pages)
@misc{healthcanadahcp2018,
  title = {Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids},
  author = {{Health Canada}},
  year = {2018},
  note = {Spring 2018. Section 1.0, The Endocannabinoid System},
  url = {https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html}
}
@misc{healthcanadaaboutcannabis,
  title = {About cannabis},
  author = {{Health Canada}},
  url = {https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/about.html},
  note = {Accessed 27 September 2026}
}
@misc{healthcanadacbd,
  title = {Cannabidiol (CBD)},
  author = {{Health Canada}},
  url = {https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/about/cannabidiol.html},
  note = {Accessed 27 September 2026}
}
@article{laprairie2015,
  title = {Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor},
  author = {Laprairie RB and others},
  journal = {Br J Pharmacol},
  year = {2015},
  doi = {10.1111/bph.13250}
}
@article{englund2013,
  title = {Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment},
  author = {Englund A and others},
  journal = {J Psychopharmacol},
  year = {2013},
  doi = {10.1177/0269881112460109},
  note = {PMID: 23042808}
}
@article{englund2023,
  title = {Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios},
  author = {Englund A and others},
  journal = {Neuropsychopharmacology},
  year = {2023},
  doi = {10.1038/s41386-022-01478-z}
}
@article{zamarripa2023,
  title = {Assessment of orally administered Δ9-tetrahydrocannabinol when coadministered with cannabidiol on Δ9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial},
  author = {Zamarripa CA and others},
  journal = {JAMA Netw Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2022.54752}
}
@article{chesney2025,
  title = {Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial},
  author = {Chesney E and others},
  journal = {Neuropsychopharmacology},
  year = {2025},
  doi = {10.1038/s41386-025-02175-3},
  note = {PMID: 40702165}
}
@misc{sativexsmpc,
  title = {Sativex oromucosal spray: Summary of Product Characteristics},
  journal = {Electronic Medicines Compendium},
  url = {https://www.medicines.org.uk/emc/product/602/smpc}
}
@misc{nabilonesmpc,
  title = {Nabilone 1 mg capsules: Summary of Product Characteristics},
  journal = {Electronic Medicines Compendium},
  url = {https://www.medicines.org.uk/emc/product/12767/smpc}
}
@misc{mhraspecials,
  title = {The supply of unlicensed medicinal products (“specials”)},
  author = {{Medicines and Healthcare products Regulatory Agency}},
  journal = {GOV.UK},
  url = {https://www.gov.uk/government/publications/supply-unlicensed-medicinal-products-specials}
}
@misc{nhscbpm,
  title = {Cannabis-based products for medicinal use (CBPMs)},
  author = {{NHS England}},
  journal = {NHS England},
  url = {https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/}
}
% NWPT-048 end